Alliance Pharma and Drug Development Solutions Are Now Resolian
May 18th, 2023 8:00 AM / by Alliance Pharma
Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.
Alliance Pharma Opens State-of-the-Art Bioanalytical Laboratory in Brisbane
December 7, 2022 8:00 AM / by Alliance Pharma
MALVERN, Pa.; December 7, 2022 (Business Wire) – Alliance Pharma (Alliance), a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.
The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioanalytical support.
U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia
MALVERN, Pa. and BRISBANE, Australia; Aug. 11, 2022 – Alliance Pharma (Alliance), a global leader in bioanalytical and CMC testing services in the pharmaceutical and biopharmaceutical industry, today announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.
Alliance Pharma Pty, Ltd. will contain an expansive state-of-the-art lab, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will . . .
U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business
Expands bioanalytical services to include many emerging areas worldwide
MALVERN, Pa.; July 13, 2022 (Business Wire) – Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company.
AlliancePharma Announces Launch of Professional Services Quoting Application, PSQuote from CLD Partners
Apr 29, 2022 3:57:19 PM / by Alliance Pharma
MALVERN, Pa., April 29, 2022 /PRNewswire/ -- This week, AlliancePharma (Malvern, PA) announced their go-live of PSQuote together with CLD Partners (Front Royal, VA). PSQuote is a newly developed professional services quoting application built on the Salesforce platform (PSQuote is a wholly-owned division of CLD Partners). AlliancePharma will use the tool to enhance and elevate their sales cycle, delivering a better customer sales experience--from quote to service delivery. CLD Partners has engaged with AlliancePharma since June 2021, for FinancialForce implementation services, and this new deployment is the next step in a growing business relationship. . .
Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer
Apr 12, 2022 4:51:57 PM / by Alliance Pharma
Malvern, PA, March 25, 2022 - Alliance Pharma, a leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, announces that Patrick Bennett has been named Chief Executive Officer. Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and . . .
Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO
Nov 19, 2021 10:23:36 AM / by Alliance Pharma
WELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, and cell and gene therapy assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.